Needham, Massachusetts, USA,August 20, 2026
Evolved By Nature, Inc. announced that its programmable peptide platform has been used in the development of New Day™ Skin Spray, a prescription topical therapy for the management of atopic dermatitis and skin dryness. Developed and commercialized by Evolved Health, Inc., New Day™ Skin Spray has received FDA 510(k) clearance as a prescription medical device and is beginning an initial launch in select markets. The product uses a soluble silk fibroin peptide derived from Evolved By Nature’s platform, representing the first product based on the company’s peptide technology to complete the development and regulatory process required to reach patients in a regulated medical field.
Peptide Technology Targets the Skin Barrier
Atopic dermatitis is characterized in the announcement as a skin-barrier disorder, in which disruption of the skin’s protective barrier can contribute to exposure to irritants, allergens and microbes and help sustain inflammatory responses. New Day™ Skin Spray is designed to address the skin barrier rather than primarily targeting the downstream immune response. According to Evolved By Nature, the soluble silk fibroin peptide forms a flexible, breathable surface architecture after application that reinforces compromised skin and helps limit penetration by external irritants and pathogens, including Staphylococcus aureus. The company positions the technology as a non-steroidal prescription option with no systemic exposure. By supporting the skin’s physical barrier, the product is intended to reduce factors that can contribute to recurring irritation and allow the skin to recover. The approach highlights a different strategy for managing atopic dermatitis by focusing on the structural integrity of the skin rather than directly suppressing inflammation. New Day™ Skin Spray is indicated for the management of dryness of skin and atopic dermatitis and is intended for topical use under the direction of a healthcare practitioner. The product does not contain corticosteroids, according to the company’s safety information. The announcement states that the device is contraindicated for individuals with known hypersensitivity to any of its ingredients.
FDA Clearance Marks Platform Milestone
The FDA 510(k) clearance represents an important milestone for Evolved By Nature’s peptide technology platform. The company said it has spent more than a decade developing its manufacturing and peptide capabilities, with the platform now reportedly capable of producing approximately 900 metric tons annually. Evolved By Nature develops and manufactures its peptide platform, while purpose-built companies can apply the technology to regulated products. Evolved Health developed New Day™ Skin Spray and is commercializing the product in partnership with PHILRx, a specialty pharmacy partner. The initial launch is taking place in select markets, with broader availability expected to follow. The company views the regulatory milestone as evidence of the platform’s potential to support additional applications across healthcare and other areas. Evolved By Nature also highlighted the growing role of artificial intelligence in peptide discovery and development. The company says AI is being used to accelerate its ability to map, predict and productize molecules from its broader library, potentially supporting future applications in healthcare, biologics, natural ingredients and other fields.
Advertisement
Expanding Programmable Peptides Into Healthcare
The development of New Day™ Skin Spray demonstrates how peptide-based technologies can move from platform research toward regulated healthcare applications. Evolved By Nature’s strategy combines peptide manufacturing capabilities with partnerships designed to carry individual technologies into specific markets. The company says its platform has generated a library of patented and safety-demonstrated molecules and that it is continuing to explore applications across multiple industries. For the atopic dermatitis market, New Day™ Skin Spray introduces a topical, non-steroidal approach focused on skin-barrier management. Its FDA clearance and initial prescription launch provide an important commercial milestone for the companies involved while also demonstrating the potential application of soluble silk fibroin peptides in medical devices. As the product reaches patients through its initial launch, its adoption and broader market availability will provide further insight into the practical role of programmable peptide technology in dermatological care. The development also underscores the increasing convergence of biotechnology, advanced materials and regulated medical products in the treatment and management of chronic skin conditions.
Source: Evolved By Nature press relese
